Wedbush Maintains Outperform on Immunome, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten maintains an Outperform rating on Immunome (NASDAQ:IMNM) and raises the price target from $27 to $33.
April 01, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten maintains an Outperform rating on Immunome and raises the price target from $27 to $33.
The increase in price target by a reputable analyst suggests a positive outlook on Immunome's stock, likely leading to increased investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100